Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men-Reference-Cited by-同舟云学术

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men

Published:2005-08-10 Issue:1 Volume:17 Page:1-7
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Reginster Jean-Yves,Abadie Eric,Delmas Pierre,Rizzoli René,Dere Willard,van der Auwera Philippe,Avouac Bernard,Brandi Maria-Luisa,Daifotis Anastasia,Diez-Perez Adolfo,Calvo Gonzalo,Johnell Olof,Kaufman Jean-Marc,Kreutz Gottfried,Laslop Andrea,Lekkerkerker Fritz,Mitlak Bruce,Nilsson Per,Orloff John,Smillie Mary,Taylor Andrew,Tsouderos Yannis,Ethgen Dominique,Flamion Bruno

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s00198-005-1984-3.pdf

Reference50 articles.

1. Committee for Proprietary Medicinal Products (CPMP) (2001) Note for guidance on postmenopausal osteoporosis in women. London CPMP/EWP/552/95

2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

3. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468

4. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103–111

5. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 12:1–12

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis;Osteoporosis International;2022-10-25

2. Management of Osteoporosis in Men: A Narrative Review;International Journal of Molecular Sciences;2021-12-20

3. Biochemical markers of bone turnover in osteoporosis;Marcus and Feldman's Osteoporosis;2021

4. Recent advances in models for screening potential osteoporosis drugs;Expert Opinion on Drug Discovery;2018-06-05

5. New and developing pharmacotherapy for osteoporosis in men;Expert Opinion on Pharmacotherapy;2018-01-19